{
    "clinical_study": {
        "@rank": "8128", 
        "arm_group": [
            {
                "arm_group_label": "Indomethacin", 
                "arm_group_type": "Experimental", 
                "description": "Indomethacin 100 mg PR x 1 in peri-procedural period"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo suppositories (#2)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess whether peri-procedural administration of rectal\n      indomethacin, compared to placebo, can reduce the incidence of post-ERCP pancreatitis."
        }, 
        "brief_title": "Rectal Indomethacin to Prevent Post-ERCP Pancreatitis", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Post-ERCP Acute Pancreatitis", 
        "condition_browse": {
            "mesh_term": "Pancreatitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Scheduled for an ERCP at Dartmouth-Hitchcock\n\n          2. Age greater than 18 years old\n\n          3. Ability to provide written informed consent\n\n        Exclusion Criteria:\n\n          1. Inability to provide written informed consent\n\n          2. ERCP being performed for diagnosis and/or treatment of acute pancreatitis\n\n          3. Current ongoing acute pancreatitis\n\n          4. Previously documented allergy to NSAID\n\n          5. Contra-indication to NSAID therapy (creatinine level >1.4 or active peptic ulcer\n             disease), already taking NSAIDs (other than aspirin therapy for cardioprotection)\n\n          6. Pregnant or nursing mothers"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "1398", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01774604", 
            "org_study_id": "CPHS#23749"
        }, 
        "intervention": [
            {
                "arm_group_label": "Indomethacin", 
                "description": "100 mg Indomethacin PR x 1", 
                "intervention_name": "Indomethacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Indomethacin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Post ERCP acute pancreatitis", 
            "Post FNA acute pancreatitis", 
            "Indomethacin", 
            "Rectal NSAIDS"
        ], 
        "lastchanged_date": "November 22, 2013", 
        "location": {
            "contact": {
                "email": "john.m.levenick@hitchcock.org", 
                "last_name": "John M Levenick, MD", 
                "phone": "603-650-8150"
            }, 
            "contact_backup": {
                "email": "timothy.b.gardner@hitchcock.org", 
                "last_name": "Timothy B Gardner, MD", 
                "phone": "6036508150"
            }, 
            "facility": {
                "address": {
                    "city": "Lebanon", 
                    "country": "United States", 
                    "state": "New Hampshire", 
                    "zip": "03756"
                }, 
                "name": "Dartmouth-Hitchcock Medical Center"
            }, 
            "investigator": [
                {
                    "last_name": "John M Levenick, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Timothy B Gardner, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Stuart R Gordon, MD", 
                    "role": "Principal Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Rectal Indomethacin to Prevent Post-ERCP Pancreatitis", 
        "overall_contact": {
            "email": "john.m.levenick@hitchcock.org", 
            "last_name": "John M Levenick, MD", 
            "phone": "6036508150"
        }, 
        "overall_contact_backup": {
            "email": "timothy.b.gardner@hitchcock.org", 
            "last_name": "Timothy B Gardner, MD", 
            "phone": "6036508150"
        }, 
        "overall_official": {
            "affiliation": "Dartmouth-Hitchcock Medical Center", 
            "last_name": "John M Levenick, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assess whether rectal indomethacin, compared to placebo, will lower the rate of post-ERCP pancreatitis in all patients", 
            "measure": "Rate of post-ERCP pancreatitis in all patients", 
            "safety_issue": "Yes", 
            "time_frame": "30 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01774604"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assess the difference in severity of post-ERCP pancreatitis in patients who develop this condition", 
                "measure": "Severity of post-ERCP pancreatitis", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }, 
            {
                "description": "Assess the rates of post-fine needle aspiration (FNA) pancreatitis in the setting of concomitant ERCP/endoscopic ultrasound examinations", 
                "measure": "Post-fine needle aspiration pancreatitis in setting of concomitant ERCP/EUS", 
                "safety_issue": "Yes", 
                "time_frame": "30 days"
            }
        ], 
        "source": "Dartmouth-Hitchcock Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dartmouth-Hitchcock Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}